レプリジェンは2025年度に強い成果を掲げ,18%の収入増加と,困難にもかかわらず2026年度の展望を高めた. Repligen posted strong 2025 results with 18% revenue growth and raised 2026 outlook despite challenges.

Repligenは,第4四半期と2025年全年の業績を強く報告し,第4四半期は1億8,300万ドルの収益,全年7億3,800万ドルの収益を上げ,報告された18%と有機成長の14%を反映した. Repligen reported strong fourth-quarter and full-year 2025 results, with revenue of $198 million in Q4 and $738 million for the year, reflecting 18% reported and 14% organic growth. 調整されたEPSはQ4で0.49に達した. ^ "0.44から昇格,完全調整EPSは1.71ドル,過度な案内だった. Adjusted EPS reached $0.49 in Q4, up from $0.44, and full-year adjusted EPS was $1.71, exceeding guidance. 同社は,タンパク質,プロセス分析,染色体学を含む主要なセグメントで2桁の成長を示し,総利益率は年間52.6%に拡大しました. The company saw double-digit growth across key segments, including Proteins, Process Analytics, and Chromatography, while gross margin expanded to 52.6% for the year. 2026年,レプリゲンは8億10000万ドルから8億4000万ドルまでの収益を予測し,遺伝子療法のプラットフォームとマクロ経済の不安定さにかかわらず,継続的なマージンの拡大が期待される. For 2026, Repligen projected revenue between $810 million and $840 million, with continued margin expansion expected despite headwinds from a gene therapy platform and macroeconomic uncertainty.